Proviva Therapeutics Ltd. scientists hypothesized that both the activation of IL-2 receptor (IL-2R) and the blockade of programmed cell death protein 1 (PD-1) are complementary and potentially synergistic as a combination therapy for treating cancer.
HSN-003839 is a ubiquitin carboxyl-terminal hydrolase 21 (USP21) inhibitor discovered by Beijing Pharscin Innobio Co. Ltd. and being developed as a novel anticancer agent.
By a unanimous 12-0 vote, the U.S. FDA’s Oncologic Drugs Advisory Committee concluded that new evidence support the use of minimal residual disease (MRD) as an accelerated approval endpoint in multiple myeloma (MM) clinical trials. The FDA will now consider the recommendation, which, if incorporated into future studies, could dramatically shorten some drug developer timelines and offer more options for treating the aggressive bone marrow cancer.
The University of Florida Health Proton Therapy Institute’s director of Physics, Perry Johnson, has filed for protection of a method for patient posture and alignment using mixed reality (MixR) visualization.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described Toll-like receptor 7 (TLR7) and/or TLR8 agonists and their immunostimulatory antibody conjugates (ISACs) consisting of antibodies covalently linked to TLR7 and/or TLR8 agonists through cleavable or uncleavable linkers.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
RSS
